What is the recommended treatment for onychomycosis?

Onychomycosis Treatment

For dermatophyte onychomycosis, oral terbinafine 250 mg daily for 12-16 weeks (toenails) or 6 weeks (fingernails) is the first-line treatment, demonstrating superior efficacy with 55% complete cure rates and significantly lower relapse rates (23%) compared to itraconazole (26% cure, 53% relapse). 1

Treatment Algorithm by Severity

Mild Onychomycosis (<20% nail involvement, distal/superficial)

• Topical monotherapy: Amorolfine 5% lacquer once or twice weekly for 6-12 months 1
• Alternative: Ciclopirox 8% lacquer daily for up to 48 weeks 1
• Efinaconazole 10% is preferred in North American guidelines 2, 3, 4

Moderate Onychomycosis (20-60% involvement)

• Combination therapy: Oral terbinafine PLUS topical antifungal 1, 3, 4
• If oral therapy contraindicated: Topical efinaconazole alone 3

Severe Onychomycosis (>60% involvement, matrix involvement, or dermatophytoma)

• Oral terbinafine 250 mg daily for 12-16 weeks (toenails) or 6 weeks (fingernails) 1
• Consider adding topical therapy for enhanced efficacy 1

Systemic Treatment Options (Ranked by Efficacy)

First-Line: Terbinafine (Strength of Recommendation A)

• Dosing: 250 mg daily for 6 weeks (fingernails), 12-16 weeks (toenails) 1
• Efficacy: 55% complete cure at 72 weeks; 46% mycological cure at 5 years 1
• Monitoring: Baseline liver function tests and complete blood count in patients with hepatotoxicity history, heavy alcohol use, or hepatitis 1
• Key advantage: Minimal drug interactions (only CYP2D6 substrates) 1
• Critical warning: Permanent taste disturbance is rare but possible—counsel patients 1

Second-Line: Itraconazole (Strength of Recommendation A)

• Dosing options:
  • Continuous: 200 mg daily for 12 weeks 1
  • Pulse therapy: 400 mg daily for 1 week/month (2 pulses for fingernails, 3 for toenails) 1
• Efficacy: 26% complete cure at 72 weeks; 13% mycological cure at 5 years 1
• Monitoring: Hepatic function tests if pre-existing abnormalities, continuous therapy >1 month, or concomitant hepatotoxic drugs 1
• Take with food and acidic pH for optimal absorption 1
• Contraindication: Heart failure 1

Third-Line: Fluconazole (Strength of Recommendation B)

• Dosing: 150-450 mg weekly for 3 months (fingernails), ≥6 months (toenails) 1
• Efficacy: 47-62% mycological cure (toenails), 89-100% (fingernails) 1
• Use when: Terbinafine or itraconazole not tolerated 1
• Advantage: Once-weekly dosing improves compliance 1
• Note: Not licensed for onychomycosis but evidence-supported 1

Fourth-Line: Griseofulvin (Strength of Recommendation C)

• Dosing: 500-1000 mg daily for 6-9 months (fingernails), 12-18 months (toenails) 1
• Take with fatty food to increase absorption 1
• Lower efficacy and higher relapse rates—reserve for when other options contraindicated 1

Pediatric Dosing (Ages 1-12 years)

Terbinafine (First-line, generally preferred)

• <20 kg: 62.5 mg daily
• 20-40 kg: 125 mg daily

• 40 kg: 250 mg daily

• Duration: 6 weeks (fingernails), 12 weeks (toenails)
• Unlicensed in children—baseline monitoring required 1

Itraconazole (First-line alternative)

• Pulse therapy: 5 mg/kg daily for 1 week/month (2 pulses for fingernails, 3 for toenails) 1

Critical Clinical Pearls

Before Starting Treatment

1. Confirm diagnosis mycologically—approximately 50% of nail dystrophies are non-fungal 5, 6
2. Microscopy, culture, and/or molecular testing from nail scrapings 7, 5
3. Identify causative organism—treatment differs for dermatophytes vs. yeasts vs. non-dermatophyte molds 1

Re-evaluation Timeline

• Reassess at 3-6 months after treatment initiation 1
• Continue treatment if disease persists 1
• Complete cure requires both mycological cure AND clinical cure 5

Common Pitfalls to Avoid

1. Starting treatment without mycological confirmation—leads to unnecessary systemic antifungal exposure 7, 5, 6
2. Inadequate treatment duration—nail growth takes 12-18 months for toenails 2
3. Not addressing concurrent tinea pedis—major source of reinfection 5
4. Ignoring contraindications: Active liver disease for terbinafine; heart failure for itraconazole 1

Specialist Referral Indications

Refer when: treatment failure, severe disease, dermatophytoma present, nail matrix involvement, multiple comorbidities, or immunocompromised status 5

Prevention Counseling

• Discard old footwear or treat with antifungal powder/spray 1
• Keep nails short 1
• Treat all infected family members simultaneously 1
• Address predisposing factors: diabetes, immunosuppression, concurrent tinea pedis 5